editor
newli
identifi
human
bocaviru
hbov
member
parvoviru
famili
suspect
infect
cell
respiratori
tract
thu
may
etiolog
agent
respiratori
diseas
human
although
koch
postul
fulfil
hbov
appear
like
caus
substanti
number
respiratori
tract
infect
least
children
describ
case
sever
atyp
pneumonia
associ
hbov
dna
bronchoalveolar
lavag
bal
sampl
adult
patient
caucasian
woman
angioimmunoblast
lymphoma
nhl
chang
highli
malign
blastic
bcell
lymphoma
bnhl
state
cell
initi
stage
iiib
patient
previous
treat
vincristin
prednison
follow
chemotherapi
accord
protocol
cycl
novemb
januari
januari
februari
chemotherapi
combin
antimicrobi
drug
therapi
accord
rdhap
protocol
includ
dexamethason
chemotherapi
drug
cytarabin
cisplatin
monoclon
antibodi
drug
rituximab
persist
symptom
bcell
lymphoma
regimen
follow
therapi
switch
alemtuzumab
ifosfamid
carboplatin
etoposid
march
led
therapyinduc
leukopenia
thrombocytopenia
high
fever
end
march
begin
april
may
second
round
alemtuzumab
ifosfamid
carboplatin
etoposid
chemotherapi
initi
june
therapyinduc
hemorrhag
cystiti
occur
juli
patient
ongo
high
fever
aplasia
bone
marrow
unclear
etiolog
juli
hospit
treatment
initi
consist
antimicrobi
drug
treatment
ceftriaxon
mg
daili
gentamicin
mg
daili
antimycot
therapi
start
caspofungin
mg
daili
sinc
cytomegaloviru
cmv
infect
suspect
ganciclovir
mg
twice
daili
administ
iv
week
although
patient
report
ongo
cough
pneumonialik
symptom
sever
atyp
pneumonia
refract
antibacteri
antimycot
treatment
diagnos
first
time
hospit
treatment
comput
tomographi
scan
show
bilater
atyp
reticulonodular
infiltr
predomin
lower
zone
lung
figur
bal
obtain
exacerb
pulmonari
symptom
test
mycobacterium
tuberculosi
chlamydia
pneumonia
pneumocysti
jirovecii
aspergillu
sp
candida
sp
cryptococcu
neoforman
cmv
epsteinbarr
viru
hepat
b
viru
hepat
c
viru
hiv
herp
simplex
viru
varicellazost
viru
pcr
cultur
cultiv
result
neg
except
temporarili
weak
reactiv
aspergillu
antigen
serum
cmv
dna
peripher
blood
lymphocyt
posit
becam
neg
ganciclovir
therapi
archiv
portion
bal
assay
retrospect
pcrrevers
human
bocaviru
respiratori
syncyti
viru
human
coronavirus
includ
sever
acut
respiratori
coronaviru
influenza
viru
human
metapneumoviru
hmpv
posit
result
obtain
human
bocaviru
confirm
sequenc
analysi
pcr
product
within
day
patient
symptom
decreas
discharg
hospit
day
despit
ongo
bone
marrow
aplasia
antimicrobi
antimycot
prophylaxi
includ
trimethoprimsulfamethoxazol
mg
daili
voriconazol
mg
twice
daili
clinic
observ
led
primari
assumpt
fever
cough
pulmonari
symptom
like
caus
postchemotherapeut
extend
bone
marrow
aplasia
cmv
infect
accompani
unclear
bacteri
fungustyp
infect
retrospect
howev
human
bocaviru
dna
archiv
bal
strongli
suggest
pulmonari
symptom
caus
agent
rather
yet
unknown
bacteri
fungal
infect
thu
clinic
episod
describ
like
caus
agent
respons
sever
pneumonia
recent
describ
bocaviru
respiratori
virus
respiratori
syncyti
viru
hmpv
hbov
seem
preval
etiolog
agent
acut
lower
respiratori
tract
infect
children
recent
evid
human
bocaviru
infect
report
children
year
age
previous
limit
data
adult
includ
immunocompromis
patient
avail
case
describ
support
hypothesi
propos
newli
identifi
respiratori
virus
name
pathogen
also
contribut
sever
infect
adult
patient
high
risk
exampl
hmpv
found
stemcel
transplant
recipi
underw
bal
lower
respiratori
tract
infect
highrisk
patient
hmpv
also
induc
fatal
infect
find
led
conclus
new
viru
induc
ident
clinic
symptom
like
human
bocaviru
may
also
contribut
sever
respiratori
infect
summari
first
report
respiratori
tract
infect
hbov
adult
immunocompromis
patient
strongli
support
assumpt
hbov
emerg
pathogen
requir
attent
even
adult
patient
